Adalimumab Biosimilar（Rani Therapeutics）

阿达木单抗生物类似药（Rani Therapeutics）

Report date: 2025/03/14 18:03:17

Base Information

Drug NameAdalimumab Biosimilar（Rani Therapeutics）
Drug Alias NameOral adalimumab（Rani Therapeutics）口服阿达木单抗（Rani Therapeutics）orally administered adalimumab biosimilar（Rani Therapeutics）RT-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidArthritis, Psoriatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRani Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesRani Therapeutics LlcRani Therapeutics Holdings Inc
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidArthritis, Psoriatic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A